Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

More articles from Clinical Investigation

  • <sup>64</sup>Cu Treatment Planning and <sup>67</sup>Cu Therapy with Radiolabeled [<sup>64</sup>Cu/<sup>67</sup>Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry
    You have access
    64Cu Treatment Planning and 67Cu Therapy with Radiolabeled [64Cu/67Cu]MeCOSar-Octreotate in Subjects with Unresectable Multifocal Meningioma: Initial Results for Human Imaging, Safety, Biodistribution, and Radiation Dosimetry
    Dale L. Bailey, Kathy P. Willowson, Matthew Harris, Colin Biggin, Alireza Aslani, Nigel A. Lengkeek, Jon Stoner, M. Enid Eslick, Harry Marquis, Michelle Parker, Paul J. Roach and Geoffrey P. Schembri
    Journal of Nuclear Medicine May 1, 2023, 64 (5) 704-710; DOI: https://doi.org/10.2967/jnumed.122.264586
  • Response Prediction Using <sup>18</sup>F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy
    You have access
    Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy
    Xinying Hu, Tao Zhou, Jiazhong Ren, Jinghao Duan, Hongbo Wu, Xiaoli Liu, Zhengshuai Mu, Ning Liu, Yuchun Wei and Shuanghu Yuan
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 625-631; DOI: https://doi.org/10.2967/jnumed.122.264638
  • Prognostic Value of Tumor Volume Assessment on PSMA PET After <sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
    You have access
    Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
    Felix Kind, Ann-Christin Eder, Cordula A. Jilg, Philipp E. Hartrampf, Philipp T. Meyer, Juri Ruf and Kerstin Michalski
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 605-610; DOI: https://doi.org/10.2967/jnumed.122.264489
  • <sup>18</sup>F-AlF-NOTA-Octreotide Outperforms <sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
    You have access
    18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
    Elin Pauwels, Frederik Cleeren, Térence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans and Christophe M. Deroose
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 632-638; DOI: https://doi.org/10.2967/jnumed.122.264563
  • You have access
    Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
    Mahnoosh Naeimi, Peter L. Choyke, Katharina Dendl, Yuriko Mori, Fabian Staudinger, Tadashi Watabe, Stefan A. Koerber, Manuel Röhrich, Jürgen Debus, Clemens Kratochwil, Uwe Haberkorn and Frederik L. Giesel
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 618-622; DOI: https://doi.org/10.2967/jnumed.122.264941
  • A Single-Arm, Low-Dose, Prospective Study of <sup>177</sup>Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    You have access
    A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
    Guochang Wang, Jie Zang, Yuanyuan Jiang, Qingxing Liu, Huimin Sui, Rongxi Wang, Xinrong Fan, Jingjing Zhang, Zhaohui Zhu and Xiaoyuan Chen
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 611-617; DOI: https://doi.org/10.2967/jnumed.122.264857
  • Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using <sup>11</sup>C-Acetate PET
    You have access
    Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using 11C-Acetate PET
    Jens Sorensen, Johannes Bergsten, Tomasz Baron, Lovisa Holm Orndahl, Tanja Kero, Tomas Bjerner, Eva-Maria Hedin, Hendrik J. Harms, Rafael Astudillo and Frank A. Flachskampf
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 645-651; DOI: https://doi.org/10.2967/jnumed.122.264945
  • Prognostic Value of <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
    You have access
    Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
    Laure Michaud, Kurt Bantilan, Audrey Mauguen, Craig H. Moskowitz, Andrew D. Zelenetz and Heiko Schöder
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 536-541; DOI: https://doi.org/10.2967/jnumed.122.264740
  • Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by <sup>90</sup>Y Radioembolization: A Multicenter Retrospective Study
    You have access
    Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study
    Benedikt M. Schaarschmidt, Roman Kloeckner, Thomas Dertnig, Aydin Demircioglu, Lukas Müller, Timo Alexander Auer, Daniel Pinto dos Santos, Verena Steinle, Matthias Miederer, Bernhard Gebauer, Sonia Radunz, Stefan Kasper, Manuel Weber and Jens Theysohn
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 529-535; DOI: https://doi.org/10.2967/jnumed.122.264598
  • Phase III Study of <sup>18</sup>F-PSMA-1007 Versus <sup>18</sup>F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
    Open Access
    Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
    Pierre Olivier, Anne-Laure Giraudet, Andrea Skanjeti, Charles Merlin, Pierre Weinmann, Ines Rudolph, Alexander Hoepping and Mathieu Gauthé
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 579-585; DOI: https://doi.org/10.2967/jnumed.122.264743

Pages

  • Previous
  • Next
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 92
SNMMI

© 2025 SNMMI

Powered by HighWire